Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

he incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.